National Immunization Technical Advisory Group

Last updated

National Immunization Technical Advisory Group (NITAG) is an advisory committee consisting of multidisciplinary groups of experts responsible for providing information to national governments that is used to make evidence-based decisions regarding vaccine and immunization policy. [1] [2] The majority of industrialized and some developing countries have formally established advisory committees to guide immunization policies; other countries are working towards establishment of such committees. [3]

Contents

Purpose

The primary purpose of NITAG is to provide technical resources, supplying guidance and recommendations to national policy makers and programme managers to enable them to make evidence-based immunization related policy and program decisions. This may also include vaccination schedules regarding appropriate timing, dosage, and contraindications of vaccines. [3] To ensure that the government gives proper attention to NITAG recommendations, NITAG usually report to high level officials of the Ministry of Health. [3]

In immunization related policy, Strategic Advisory Group of Experts on Immunization (SAGE) have established mechanisms to synthesize evidence and make global recommendations. Such recommendations will be further interpreted at the country level by NITAGs. As they need to take account of factors such as local disease epidemiology, acceptability of vaccination strategies to local populations, equity in local populations, and programmatic and financial constraints. [4]

In 2011, the World Health Organization (WHO) recommended that NITAG be established in each member country. [5] The Global Vaccine Action Plan (GVAP) requested all 194 members countries to establish, or have access to, a NITAG by 2020. [6]

NITAG are considered to be functional when they meet six defined process indicators agreed upon by the WHO, which are: [7]

  1. having a legislative or administrative basis,
  2. having formal terms of reference,
  3. having at least five areas of expertise represented among its membership,
  4. having at least one meeting per year,
  5. distribution of the agenda and background documents at least one week prior to meetings, and
  6. having mandatory disclosure of conflict of interests.

As of 2022, there are 175 countries reporting existence of NITAG and 121 countries with NITAG with all six WHO functionality criteria. [8] And 85% of the world’s population is served by such NITAGs, 52% increase compared to 2010. [6]

Members

There are no fixed rules about the total number of NITAG members as it depends on local considerations such as the need for geographic representation, the size of the country, and the availability of resources. However, experience has shown that successful NITAG function with about 10–15 members. [3] NITAG members typically consist of multidisciplinary experts and represent a broad range of skills and expertise from the following disciplines/areas: clinical medicine (paediatrics and adolescent medicine, adult medicine, geriatrics), epidemiologists, infectious diseases specialists, microbiologists, public health, immunology, vaccinology, immunization programme, health systems and delivery, clinical research and health economics. [3] [9]

List of NITAG

There are no specific guideline on naming of NITAG. Therefore, NITAG in each country may have different names, for example:

Related Research Articles

<span class="mw-page-title-main">DPT vaccine</span> Combination vaccine

The DPT vaccine or DTP vaccine is a class of combination vaccines against three infectious diseases in humans: diphtheria, pertussis, and tetanus. The vaccine components include diphtheria and tetanus toxoids and either killed whole cells of the bacterium that causes pertussis or pertussis antigens. The term toxoid refers to vaccines which use an inactivated toxin produced by the pathogen which they are targeted against to generate an immune response. In this way, the toxoid vaccine generates an immune response which is targeted against the toxin which is produced by the pathogen and causes disease, rather than a vaccine which is targeted against the pathogen itself. The whole cells or antigens will be depicted as either "DTwP" or "DTaP", where the lower-case "w" indicates whole-cell inactivated pertussis and the lower-case "a" stands for "acellular". In comparison to alternative vaccine types, such as live attenuated vaccines, the DTP vaccine does not contain any live pathogen, but rather uses inactivated toxoid to generate an immune response; therefore, there is not a risk of use in populations that are immune compromised since there is not any known risk of causing the disease itself. As a result, the DTP vaccine is considered a safe vaccine to use in anyone and it generates a much more targeted immune response specific for the pathogen of interest.

<span class="mw-page-title-main">HPV vaccine</span> Class of vaccines against human papillomavirus

Human papillomavirus (HPV) vaccines are vaccines that prevent infection by certain types of human papillomavirus (HPV). Available HPV vaccines protect against either two, four, or nine types of HPV. All HPV vaccines protect against at least HPV types 16 and 18, which cause the greatest risk of cervical cancer. It is estimated that HPV vaccines may prevent 70% of cervical cancer, 80% of anal cancer, 60% of vaginal cancer, 40% of vulvar cancer, and show more than 90% efficacy in preventing HPV-positive oropharyngeal cancers. They additionally prevent some genital warts, with the quadrivalent and nonavalent vaccines that protect against HPV types HPV-6 and HPV-11 providing greater protection.

The Advisory Committee on Immunization Practices (ACIP) is a committee within the United States Centers for Disease Control and Prevention (CDC) that provides advice and guidance on effective control of vaccine-preventable diseases in the U.S. civilian population. The ACIP develops written recommendations for routine administration of vaccines to the pediatric and adult populations, along with vaccination schedules regarding appropriate timing, dosage, and contraindications of vaccines. ACIP statements are official federal recommendations for the use of vaccines and immune globulins in the U.S., and are published by the CDC.

<span class="mw-page-title-main">Pneumococcal conjugate vaccine</span> Vaccine against Strep pneumoniae

Pneumococcal conjugate vaccine is a pneumococcal vaccine and a conjugate vaccine used to protect infants, young children, and adults against disease caused by the bacterium Streptococcus pneumoniae (pneumococcus). It contains purified capsular polysaccharide of pneumococcal serotypes conjugated to a carrier protein to improve antibody response compared to the pneumococcal polysaccharide vaccine. The World Health Organization (WHO) recommends the use of the conjugate vaccine in routine immunizations given to children.

<span class="mw-page-title-main">Zoster vaccine</span> Vaccine to prevent shingles

A zoster vaccine is a vaccine that reduces the incidence of herpes zoster (shingles), a disease caused by reactivation of the varicella zoster virus, which is also responsible for chickenpox. Shingles provokes a painful rash with blisters, and can be followed by chronic pain, as well as other complications. Older people are more often affected, as are people with weakened immune systems (immunosuppression). Both shingles and postherpetic neuralgia can be prevented by vaccination.

The Joint Committee on Vaccination and Immunisation (JCVI) is an independent expert advisory committee that advises United Kingdom health departments on immunisation, making recommendations concerning vaccination schedules and vaccine safety. It has a statutory role in England and Wales, and health departments in Scotland and Northern Ireland may choose to accept its advice.

<span class="mw-page-title-main">Hepatitis B vaccine</span> Vaccine against hepatitis B

Hepatitis B vaccine is a vaccine that prevents hepatitis B. The first dose is recommended within 24 hours of birth with either two or three more doses given after that. This includes those with poor immune function such as from HIV/AIDS and those born premature. It is also recommended that health-care workers be vaccinated. In healthy people, routine immunization results in more than 95% of people being protected.

A vaccination policy is a health policy adopted in order to prevent the spread of infectious disease. These policies are generally put into place by State or local governments, but may also be set by private facilities, such as workplaces or schools. Many policies have been developed and implemented since vaccines were first made widely available.

The rotavirus vaccine is a vaccine used to protect against rotavirus infections, which are the leading cause of severe diarrhea among young children. The vaccines prevent 15–34% of severe diarrhea in the developing world and 37–96% of the risk of death among young children due to severe diarrhea. Immunizing babies decreases rates of disease among older people and those who have not been immunized.

NmVac4-A/C/Y/W-135 is the commercial name of the polysaccharide vaccine against the bacterium that causes meningococcal meningitis. The product, by JN-International Medical Corporation, is designed and formulated to be used in developing countries for protecting populations during meningitis disease epidemics.

Meningococcal vaccine refers to any vaccine used to prevent infection by Neisseria meningitidis. Different versions are effective against some or all of the following types of meningococcus: A, B, C, W-135, and Y. The vaccines are between 85 and 100% effective for at least two years. They result in a decrease in meningitis and sepsis among populations where they are widely used. They are given either by injection into a muscle or just under the skin.

<span class="mw-page-title-main">Health in Spain</span> Overview of health in Spain

In 2012, life expectancy at birth in Spain reached 82.5 years, one of the highest among OECD countries and more than two years higher than the OECD average. Only Japan, Iceland and Switzerland had a higher life expectancy than Spain in 2012. The top three causes of death since 1970 have been cardiovascular diseases, cancer and respiratory diseases.

<span class="mw-page-title-main">Vaccines for Children Program</span>

The Vaccines for Children Program (VFC) is a federally funded program in the United States providing no-cost vaccines to children who lack health insurance or who otherwise cannot afford the cost of the vaccination. The VFC program was created by the Omnibus Budget Reconciliation Act of 1993 and is required to be a new entitlement of each state's Medicaid plan under section 1928 of the Social Security Act. The program was officially implemented in October 1994 and serves eligible children in all U.S. states, as well as the Commonwealth of Puerto Rico, the U.S. Virgin Islands, American Samoa, Guam, and the Commonwealth of the Northern Mariana Islands.

<span class="mw-page-title-main">Tetanus vaccine</span> Vaccines used to prevent tetanus

Tetanus vaccine, also known as tetanus toxoid (TT), is a toxoid vaccine used to prevent tetanus. During childhood, five doses are recommended, with a sixth given during adolescence.

Universal Immunisation Programme (UIP) is a vaccination programme launched by the Government of India in 1985. It became a part of Child Survival and Safe Motherhood Programme in 1992 and is currently one of the key areas under the National Health Mission since 2005. The programme now consists of vaccination for 12 diseases- tuberculosis, diphtheria, pertussis, tetanus, poliomyelitis, measles, hepatitis B, rotaviral gastroenteritis, Japanese encephalitis, rubella, pneumonia and Pneumococcal diseases. Hepatitis B and Pneumococcal diseases were added to the UIP in 2007 and 2017 respectively. The cost of all the vaccines are borne entirely by the Government of India and is funded through taxes with a budget of 7,234 crore (US$910 million) in 2022 and the program covers all residents of India, including foreign residents.

The Standing Committee on Vaccination at the Robert Koch Institute, or STIKO, is a scientific committee comprising 18 members at the Robert Koch Institute in Berlin, Germany that provides official recommendations for the vaccination schedules used by the individual German states. The committee meets twice yearly to review the latest research regarding vaccination against infectious diseases. Although the STIKO makes recommendations, immunization in Germany is voluntary and there are no official government recommendations. German Federal States typically follow the STIKO's recommendations minimally, although each state can make recommendations for their geographic jurisdiction that extends beyond the recommended list. In addition to the proposed immunization schedule for children and adults, the STIKO recommends vaccinations for occupational groups, police, travelers, and other at risk groups.

The Strategic Advisory Group of Experts (SAGE) is the principal advisory group to World Health Organization (WHO) for vaccines and immunization. Established in 1999 through the merging of two previous committees, notably the Scientific Advisory Group of Experts and the Global Advisory Group by Director-General of the WHO Gro Harlem Brundtland. It is charged with advising WHO on overall global policies and strategies, ranging from vaccines and biotechnology, research and development, to delivery of immunization and its linkages with other health interventions. SAGE is concerned not just with childhood vaccines and immunization, but all vaccine-preventable diseases. SAGE provide global recommendations on immunization policy and such recommendations will be further translated by advisory committee at the country level.

Helen Aspasia Petousis-Harris is a New Zealand vaccinologist and associate professor in the Department of General Practice and Primary Health Care at the University of Auckland. She has been involved in research related to vaccination in New Zealand since 1998, with her main areas of focus being vaccine safety and effectiveness. Petousis-Harris has had a variety of lead roles in New Zealand and international organisations that focus on vaccination and is a regular media spokesperson in this field, especially during the COVID-19 pandemic.

The National Advisory Committee on Immunization is an advisory body that provides the Government of Canada with medical and scientific advice relating to human immunization.

The Australian Technical Advisory Group on Immunisation (ATAGI) is a technical advisory group of the Australian Government. As part of the Department of Health, ATAGI provides advice to the Minister of Health on the immunisation program of Australia and related matters, including the strength of evidence pertaining to existing, new, and emerging vaccines.

References

  1. Gessner, Bradford D.; Duclos, Philippe; DeRoeck, Denise; et al. (19 April 2010). "Informing decision makers: Experience and process of 15 National Immunization Technical Advisory Groups". Vaccine. Elsevier. 28 (1): A6-12. doi:10.1016/j.vaccine.2010.02.025. PMID   20412988.
  2. "National advisory committees on immunization". who.int. WHO. June 2019. Retrieved 22 January 2020.
  3. 1 2 3 4 5 Duclos, Philippe (19 April 2010). "National Immunization Technical Advisory Groups (NITAGs): Guidance for their establishment and strengthening" (PDF). Vaccine. Elsevier. 28 (1): A18-25. doi:10.1016/j.vaccine.2010.02.027. PMID   20412991.
  4. Steffen, Christoph A.; Henaff, Louise; Durupt, Antoine; et al. (8 April 2021). "Evidence-informed vaccination decision-making in countries: Progress, challenges and opportunities". Vaccine. Elsevier. 39 (15): 2146–2152. doi: 10.1016/j.vaccine.2021.02.055 . PMID   33712350.
  5. Duclos, Philippe; Dumolarda, Laure; Abeysingheb, Nihal; et al. (2013). "Progress in the establishment and strengthening of national immunization technical advisory groups: Analysis from the 2013 WHO/UNICEF joint reporting form, data for 2012". Vaccine. Elsevier (published 4 November 2013). 31 (46): 5314–5320. doi: 10.1016/j.vaccine.2013.08.084 . PMID   24055304.
  6. 1 2 WHO (2019). The Global Vaccine Action Plan 2011-2020 • Review And Lessons Learned. Geneva: WHO.
  7. "SAGE April 2017 - NITAGs - Background Paper" (PDF). World Health Organization. April 2017.
  8. "National Immunization Advisory Mechanism". World Health Organization . Retrieved 15 September 2023.
  9. "ACIP charter". National Center for Immunization and Respiratory Diseases. 1 April 2014. Retrieved 20 November 2015.
  10. "Vaccine Committee". Haute Autorité de Santé. 14 September 2019. Retrieved 29 January 2020.
  11. "Press Note". Government of India Press Information Bureau. 8 February 2017. Retrieved 29 January 2020.
  12. "Notification No.F.EPI-NITAG/2014" (PDF). Ministry of National Health Services, Regulation and Coordination. 19 May 2014. Retrieved 10 December 2023.